Sharemaestro Newsreel

Neogen Corp (NASDAQ: NEOG) CEO notes son's indirect buy of 370 shares

Neogen Corp CEO Mikheal Nassif reported an indirect purchase of 370 shares of Common Stock at $11.81 per share on August 4, 2026. The shares are held by his son, bringing the reported indirect holdings to 1,074 shares, though Nassif disclaims beneficial ownership. This …

TD Cowen Maintains Pacific Biosciences of California(PACB.US) With Buy Rating, Maintains Target Price $3

TD Cowen has reiterated its Buy rating on Pacific Biosciences of California (PACB.US) and maintained its target price at $3. This indicates a continued positive outlook from the firm regarding the company's stock performance.

Artivion earnings on deck: Can FDA approval revive growth? By Investing.com

Artivion Inc. is set to report its second-quarter earnings, with investors focusing on whether its recent FDA premarket approval for the AMDS Hybrid Prosthesis can counteract slowing sales and revive growth. Despite a 46% drop in shares from their 52-week high and a sequential …

All eyes on Quidel earnings as estimates tumble, asset sale looms

Quidel Corporation is set to report its second-quarter earnings after market close on Thursday, August 6, 2026, with analysts anticipating a loss of 4 cents per share. Investor confidence has waned due to declining EPS estimates and uncertainty surrounding the potential $1.5 billion sale …

Standard BioTools Inc. (LAB) Stock Price, News, Quote & History

This article provides comprehensive financial information for Standard BioTools Inc. (LAB), including its current stock price, historical data, and analyst ratings. It details the company's overview, its segments in proteomics and genomics, key products like the SomaScan platform and CyTOF technology, and financial performance …

Standard BioTools Reports Second Quarter 2026 Financial Results

Standard BioTools Inc. announced its financial results for the second quarter of 2026, reporting $20.1 million in revenue and an 84% improvement in adjusted EBITDA year-over-year. The company is progressing with its merger with Treeline Biosciences, anticipated to close before year-end 2026, and has …

Tandem Diabetes Care, Inc. (TNDM) Reports Q2 Loss, Lags Revenue Estimates

Tandem Diabetes Care, Inc. (TNDM) reported a Q2 loss of $0.31 per share, exceeding the Zacks Consensus Estimate of a $0.34 loss, marking an 8.82% surprise. Despite this, the company's Q2 revenues of $254.56 million missed the consensus estimate by 0.1%, leading to an …

LivaNova PLC (LIVN) (Q2 2026) Earnings Call Highlights: Record Revenue and EPS, Raised Guidance ...

LivaNova PLC (LIVN) reported record revenue of $391 million and adjusted EPS of $1.26 for Q2 2026, driven by strong growth in both Cardiopulmonary and Epilepsy segments. The company raised its full-year 2026 revenue guidance to 8%-9% growth and adjusted EPS guidance to $4.30-$4.40, …

Delcath Systems Inc (DCTH) Beats Revenue Estimates with $29.1 Million in Q2 Earnings: GF Score 73/100, 66.7% Undervalued

Delcath Systems Inc (DCTH) reported Q2 2026 revenue of $29.1 million, surpassing analyst estimates, driven by strong HEPZATO KIT sales. Despite increased R&D expenses, the oncology company maintained stable net income and improved gross margins. Delcath is well-positioned for future growth with a robust …

Stryker Corp To Go Ex-Dividend On September 30th, 2026 With 0.88 USD Dividend Per Share

Stryker Corp (NYSE:SYK) is set to go ex-dividend on September 30th, 2026, with a dividend payment of $0.88 per share. This financial event is important for investors to note as it affects who receives the upcoming dividend.

Outset Medical, Inc. (OM) Reports Q2 Loss, Beats Revenue Estimates

Outset Medical, Inc. (OM) reported a Q2 loss of $0.8 per share, which was wider than the Zacks Consensus Estimate of a $0.63 loss. However, the company surpassed revenue estimates, posting $31.64 million for the quarter, exceeding the consensus by 9.84%. Despite the earnings …

Insulet Valuation Attractive Despite Growth Reset Risk, RBC Says

RBC views Insulet's valuation as attractive despite potential risks associated with its growth strategy and upcoming competition. The article briefly mentions Insulet's challenges in serving Type 2 diabetes patients. Full access to the MT Newswires article requires a premium subscription.

CONMED Corporation $CNMD Shares Sold by Edgestream Partners L.P.

Edgestream Partners L.P. significantly reduced its stake in CONMED Corporation (NYSE:CNMD) during the first quarter, selling 87.4% of its shares. Despite this, CONMED reported strong quarterly earnings, surpassing analyst expectations for both EPS and revenue, and maintained its fiscal 2026 EPS guidance. Analyst sentiment …

Lucid Diagnostics Inc (LUCD) News, Articles, Events & Latest Updates

This article provides a compilation of recent news and updates regarding Lucid Diagnostics Inc. (LUCD), including coverage policies for its EsoGuard test, upcoming investor conference participations, and quarterly earnings reports from related companies. It also mentions a price target reduction for LUCD despite expected …

FMR LLC (LIVN) discloses 5.8% LivaNova stake in Schedule 13G filing

FMR LLC has filed a Schedule 13G, disclosing a beneficial ownership of 5.8% in LivaNova PLC (LIVN) common stock, amounting to 3,210,395.27 shares as of June 30, 2026. Both FMR LLC and Abigail P. Johnson reported this stake, with FMR LLC holding sole voting …

LivaNova PLC Stock 12‑Month Price Target Raised to $88.78, Implies 4% Upside

LivaNova PLC (LIVN) has seen its average 12-month price target increased from $86.78 to $88.78 by 9 analysts, with individual forecasts ranging from $75 to $95. This new target suggests a potential upside of approximately 4% from its closing price on August 4. The …

Bioventus (BVS) Stock Jumps On Profit Strength As Growth Risks Remain

Bioventus (BVS) stock surged 13.7% following a strong Q2 earnings report, showcasing adjusted EBITDA of US$35 million on US$153.2 million revenue and healthy cash generation. While the company's profitability and cash flow are positive, concerns remain regarding its reliance on a narrow product set, …

IceCure Medical Adds Adventist Health as U.S. Clinical Site for its Post-Marketing "ChoICE" Study for Low-Risk Breast Cancer Cryoablation Treatment

IceCure Medical has announced that Adventist Health Glendale will be the first U.S. clinical site to enroll patients in its post-marketing "ChoICE" study for ProSense® cryoablation treatment of low-risk breast cancer. The study aims to gather real-world data on up to 400 patients across …

Zimmer Biomet Holdings, Inc. Stock 12‑Month Price Target Raised to $104.9, Implies 7% Upside

Zimmer Biomet Holdings, Inc.'s average price target has been increased to $104.9, up from $104.26, according to 20 analysts. This updated target suggests a potential 7% upside based on the Aug. 5 closing price. The consensus rating among 29 analysts remains a "Buy," with …

PacBio Q2 Earnings Meet Estimates, Revenues Miss, 2026 Sales View Cut

PacBio reported an adjusted loss per share of 14 cents for Q2 2026, meeting estimates, but revenues of $39 million missed expectations and were down 2% year over year. The company reduced its 2026 revenue guidance to $155-$165 million due to weaker instrument sales, …

UFP TECHNOLOGIES INC SEC Filing (Aug 6, 2026)

UFP Technologies Inc. (UFPT) filed a Form 144 with the SEC on August 6, 2026, indicating a proposed sale of 1100 shares of common stock by an unnamed individual. The shares, acquired via a stock award from the issuer on March 3, 2025, have …

Bronstein, Gewirtz & Grossman LLC Urges Nano-X Imaging Ltd. Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against Nano-X Imaging Ltd. (NASDAQ: NNOX) and its officers, alleging violations of federal securities laws. The lawsuit claims that Nano-X made materially false and misleading statements regarding its operations, overstating efficiency gains and demand, while facing increased …

Bronstein, Gewirtz & Grossman, LLC Encourages InMode Ltd. (INMD) Investors to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of InMode Ltd. (INMD) following a public letter from a shareholder, Steel Partners Holdings L.P. The letter alleges governance failures and suspicious stock purchases by InMode's CEO around significant corporate events, …

JPMorgan Adjusts Price Target on Zimmer Biomet to $117 From $95

JPMorgan has raised its price target for Zimmer Biomet Holdings, Inc. (ZBH) to $117 from $95. This adjustment was reported on August 6, 2026, at 12:02 pm EDT. The article also notes several other analyst adjustments for Zimmer Biomet on the same day.

Is Establishment Labs Holdings (ESTA) Undervalued After Its Earnings Beat And Raised Guidance?

UBS Adjusts Price Target on Sight Sciences to $8 From $7, Maintains Buy Rating

UBS has increased its price target for Sight Sciences (SGHT) to $8 from $7, while reiterating a Buy rating on the stock. This adjustment follows Sight Sciences' Q2 2026 earnings call and news of FDA 510(k) clearance for its OMNI Ultra Surgical System. The …

Delcath Systems Q2 Earnings Call Highlights

Delcath Systems reported strong Q2 2026 results with a 20% year-over-year revenue increase to $29.1 million, driven by a 30% rise in HEPZATO KIT volume. The company raised its full-year 2026 revenue guidance to $104 million–$108 million and expects positive adjusted EBITDA. Delcath is …

UBS Adjusts Price Target on Zimmer Biomet to $120 From $115, Maintains Buy Rating

UBS has increased its price target for Zimmer Biomet Holdings, Inc. (ZBH) to $120 from $115, while reaffirming a Buy rating on the stock. This adjustment comes amidst other analyst revisions for Zimmer Biomet on the same day, indicating active re-evaluation of the company's …

Enovis CORP 2026: Revenue $582.78M, EPS ($0.02) — 10-Q Summary

Enovis CORP (ENOV) reported its 2026 Q3 results, showing a revenue of $582.78M, a 3.2% increase year-over-year. The company significantly reduced its net loss to ($1.19M) from ($36.74M) in the prior-year quarter, with diluted EPS improving to ($0.02) from ($0.64). This performance was driven …

Establishment Labs earnings up next: Can U.S. growth sustain?

Establishment Labs is set to report Q2 earnings, with analysts expecting a loss of 34 cents per share on revenue of $65.8 million, a 28% jump year-over-year. Investors are keenly watching the medical device maker's ability to sustain growth in the U.S. market, particularly …

Establishment Labs (ESTA) lifts 2026 outlook after 31.7% Q2 revenue growth

Establishment Labs Holdings Inc. reported strong Q2 2026 revenue of $67.5 million, marking a 31.7% year-over-year increase, driven by significant growth in Motiva USA and minimally invasive platforms. The company raised its full-year 2026 revenue guidance to $269–$271 million, reflecting increased confidence in continued …

STERIS Plans $600M Chemical Manufacturing Hub, Q1 EPS Jumps 11% to $2.59

STERIS announced its largest single-site investment, a $600 million Formulated Chemistry Center of Excellence in North Carolina, alongside strong first-quarter fiscal 2027 results. The company reported an 11% increase in adjusted EPS to $2.59 and maintained its full-year revenue and EPS guidance, despite increased …

Argus Research Adjusts GE Healthcare Technologies PT to $85 From $80

Argus Research has increased its price target for GE Healthcare Technologies (GEHC) from $80 to $85, while maintaining a Buy rating on the stock. This adjustment follows the company's Q1 results which exceeded expectations and an increased adjusted EPS forecast for the year. The …

LivaNova Sees Solid Demand in Both Cardiopulmonary and Neuromodulation

Delcath Systems (NASDAQ:DCTH) Sets New 12-Month High After Better-Than-Expected Earnings

First Eagle Investment Management (QTRX) discloses 5.8% Quanterix ownership via advised funds

First Eagle Investment Management, LLC has reported a beneficial ownership of 2,753,165 shares, or 5.8% of Quanterix Corp (QTRX) common stock, as of June 30, 2026. These shares grant First Eagle sole voting and dispositive power. The First Eagle Small Cap Opportunity Fund, advised …